Melphalan Transport, Glutathione Levels, and Glutathione-S-transferase Activity in Human Medulloblastoma
Overview
Authors
Affiliations
Melphalan transport, glutathione levels, and glutathione-S-transferase activity were measured in two continuous human medulloblastoma cell lines and transplantable xenografts in athymic nude mice, TE-671 and Daoy. In vitro mean glutathione levels were 10.06 nmol/10(6) cells in TE-671 and 2.96 nmol/10(6) cells in Daoy. In vitro mean glutathione-S-transferase values were 91.52 nmol/min/mg protein in TE-671 and 50.31 nmol/min/mg protein in Daoy. Transport studies revealed kinetic parameters of Km = 108.3 microM, Vmax = 363.1 pmol/10(6) cells/min in TE-671 and Km = 111.7 microM, Vmax = 180.6 pmol/10(6) cells/min in Daoy. Melphalan transport was inhibited by both DL-alpha-2-aminobicyclo[2.2.1]heptane-2- carboxylic acid and sodium ion depletion in TE-671 and Daoy cells in vitro, indicating that both systems of amino acid transport are functional in these medulloblastoma lines. In vivo s.c. xenograft glutathione values were lower (7.79 nmol/mg protein) in TE-671 than in Daoy (13.68 nmol/mg protein). The mean plasma concentration in mice given a 10% lethal dose (71.3 mg/m2) of melphalan i.p. was 50.3 microM at 10 min, with the half-life of 29.9 min. At this dose, s.c. xenograft levels were 2- to 3-fold higher in TE-671 than in Daoy tumors for the 3-h period measured. These studies demonstrate transport parameters confirming facilitated transport of melphalan in human medulloblastoma, a mean murine plasma melphalan concentration (following treatment with melphalan) above the in vitro drug dose at which there is a 90% reduction in the number of colonies in comparison to controls for TE-671 and Daoy for 2 h, and glutathione and glutathione-S-transferase levels in the same range previously reported in other melphalan-sensitive and melphalan-resistant human tumors. Future work with spontaneous and acquired melphalan-resistant human medulloblastoma cell lines and xenografts will define the role of these mechanisms in mediating drug resistance.
Preclinical activity of melflufen (J1) in ovarian cancer.
Carlier C, Strese S, Viktorsson K, Velander E, Nygren P, Uustalu M Oncotarget. 2016; 7(37):59322-59335.
PMID: 27528037 PMC: 5312315. DOI: 10.18632/oncotarget.11163.
Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats.
Archer G, Sampson J, McLendon R, Friedman A, COLVIN O, Rose M J Neurooncol. 2000; 44(3):233-41.
PMID: 10720203 DOI: 10.1023/a:1006304424346.
Dong Q, Bullock N, Ali-Osman F, COLVIN O, Bigner D, Friedman H Cancer Chemother Pharmacol. 1996; 37(3):242-46.
PMID: 8529284 DOI: 10.1007/BF00688323.
Moscow J, Swanson C, Cowan K Br J Cancer. 1993; 68(4):732-7.
PMID: 8398701 PMC: 1968594. DOI: 10.1038/bjc.1993.419.
Lidor Y, OBriant K, Xu F, Hamilton T, Ozols R, Bast Jr R J Clin Invest. 1993; 92(5):2440-7.
PMID: 8227359 PMC: 288428. DOI: 10.1172/JCI116851.